These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37864551)

  • 21. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Weekly Dalbavancin Dosing for the Treatment of Native Vertebral Osteomyelitis Caused by Methicillin-Resistant Staphylococcus Aureus: A Case Report.
    Almangour TA; Fletcher V; Alessa M; Alhifany AA; Tabb D
    Am J Case Rep; 2017 Dec; 18():1315-1319. PubMed ID: 29222405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin vs standard of care for Staphylococcus aureus bacteraemia in patients unable to receive outpatient parenteral antimicrobial therapy.
    Frazier JD; Stoudenmire LL; Wagner JL; Thomas GM; Steele GM; Henao-Martínez AF; Franco-Paredes C; Chastain DB
    Int J Antimicrob Agents; 2023 Jul; 62(1):106842. PubMed ID: 37160242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
    Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
    [TBL] [Abstract][Full Text] [Related]  

  • 25.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacokinetic-pharmacodynamic modeling of dalbavancin, a novel glycopeptide antibiotic.
    Dowell JA; Goldstein BP; Buckwalter M; Stogniew M; Damle B
    J Clin Pharmacol; 2008 Sep; 48(9):1063-8. PubMed ID: 18633123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
    Kebriaei R; Rice SA; Stamper KC; Rybak MJ
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study.
    Karlowsky JA; Adam HJ; Poutanen SM; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):342-7. PubMed ID: 21353963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.
    Kussmann M; Karer M; Obermueller M; Schmidt K; Barousch W; Moser D; Nehr M; Ramharter M; Poeppl W; Makristathis A; Winkler S; Thalhammer F; Burgmann H; Lagler H
    Emerg Microbes Infect; 2018 Dec; 7(1):202. PubMed ID: 30514923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of plasma protein binding of dalbavancin.
    Turner NA; Xu A; Zaharoff S; Holland TL; Lodise TP
    J Antimicrob Chemother; 2022 Jun; 77(7):1899-1902. PubMed ID: 35488862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.
    Dunne MW; Puttagunta S; Giordano P; Krievins D; Zelasky M; Baldassarre J
    Clin Infect Dis; 2016 Mar; 62(5):545-51. PubMed ID: 26611777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
    Dunne MW; Puttagunta S; Sprenger CR; Rubino C; Van Wart S; Baldassarre J
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1849-55. PubMed ID: 25561338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study.
    Pascale R; Maccaro A; Mikus E; Baldassarre M; Tazza B; Esposito F; Rinaldi M; Tenti E; Ambretti S; Albertini A; Viale P; Giannella M; Bartoletti M
    J Glob Antimicrob Resist; 2022 Sep; 30():390-394. PubMed ID: 35878780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE Surveillance Program (2007).
    Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2009 Jun; 64(2):177-84. PubMed ID: 19249179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.
    Werth BJ; Jain R; Hahn A; Cummings L; Weaver T; Waalkes A; Sengupta D; Salipante SJ; Rakita RM; Butler-Wu SM
    Clin Microbiol Infect; 2018 Apr; 24(4):429.e1-429.e5. PubMed ID: 28782651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.
    Gonzalez D; Bradley JS; Blumer J; Yogev R; Watt KM; James LP; Palazzi DL; Bhatt-Mehta V; Sullivan JE; Zhang L; Murphy J; Ussery XT; Puttagunta S; Dunne MW; Cohen-Wolkowiez M
    Pediatr Infect Dis J; 2017 Jul; 36(7):645-653. PubMed ID: 28060045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.